DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Schou M, Amdisen A, Thomsen K, et al. Lithium treatment regimen
and renal water handling: the significance of dosage pattern
and tablet type examined through comparison of results from two
clinics with different treatment regimens. Psychopharmacology,
1982, 77:387–390.
Shaldubina A, Agam G, Belmaker RH. The mechanism of
lithium action: Atate of the art, ten years later. Prog Neuro-
Psychopharmacol Biol Psychiatry, 2001, 25:855–866.
Shaltiel G, Mark S, Kofman O, et al. Effect of valproate derivatives
on human brain myo- inositol-1-phosphate (MIP) synthase
activity and amphetamine- induced rearing. Pharmacol
Rep, 2007, 59:402–407.
Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic
receptor agonist xanomeline as a novel treatment approach for
schizophrenia. Am J Psychiatry, 2008, 165:1033–1039.
Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison
of first- and second- generation antipsychotics in early- onset
schizophrenia and schizo- affective disorder: findings from the
treatment of early- onset schizophrenia spectrum disorders
(TEOSS) study. Am J Psychiatry, 2008, 165:1420–1431.
Smith DA. Treatment of the dyslipidemia of insulin resistance.
Med Clin North Am, 2007, 91:1185–1210.
Soares JC, Boada F, Keshavan MS. Brain lithium measurements
with (7)Li magnetic resonance spectroscopy (MRS): A literature
review. Eur Neuropsychopharmacol, 2000, 10:151–158.
Söderpalm B. Anticonvulsants: Aspects of their mechanism of
action. Eur J Pain, 2002, 6:3–9.
Sodhi M, Wood KH, Meador- Woodruff J. Role of glutamate in
schizophrenia: Integrating excitatory avenues of research.
Expert Rev Neurother, 2008, 8:1389–1406.
Sproule B. Lithium in bipolar disorder: can drug concentrations
predict therapeutic effect? Clin Pharmacokinet, 2002, 41:
639–660.
Swerdlow NR, Light GA, Cadenhead KS, et al. Startle gating
deficits in a large cohort of patients with schizophrenia:
Relationship to medications, symptoms, neurocognition, and
level of function. Arch Gen Psychiatry, 2006, 63:1325–1335.
Tarazi FI, Zhang K, Baldessarini RJ. Long- term effects of olanzapine,
risperidone, and quetiapine on dopamine receptor
types in regions of rat brain: Implications for antipsychotic
drug treatment. J Pharmacol Exp Ther, 2001, 297:711–717.
Tarazi FI, Zhang K, Baldessarini RJ. Long- term effects of olanzapine,
risperidone, and quetiapine on serotonin 1A, 2A and
2C receptors in rat forebrain regions. Psychopharmacology,
2002, 161:263–270.
Tauscher J, Jones C, Remington G, et al. Significant dissociation
of brain and plasma kinetics with antipsychotics. Mol
Psychiatry, 2002, 7:317–321.
Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine
monotherapy in bipolar I and II depression: A doubleblind,
placebo- controlled study (the BOLDER II study). J Clin
Psychopharmacol, 2006, 26:600–609.
Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex
sodium for the treatment of acute mania and maintenance
of remission: A 47-week study. Am J Psychiatry, 2003,
160:1263–1271.
Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with
long- term lithium treatment in major affective illness: A metaanalysis.
Acta Psychiatr Scand, 2001, 104:163–172.
Tueth MJ, Murphy TK, Evans DL. Special considerations: Use
of lithium in children, adolescents, and elderly populations.
J Clin Psychiatry, 1998, 59:66–73.
Viguera AC, Newport DJ, Ritchie J, et al. Lithium in breast milk
and nursing infants: Clinical implications. Am J Psychiatry,
2007, 164:342–345.
Viguera AC, Varkula M, Donovan K,, Baldessarini RJ. Managing
health outcomes of women with schizophrenia during pregnancy
and breastfeeding. In, Medical Illness and Schizophrenia, 2nd
ed. (Meyer JM, Nasrallah HA, eds.) American Psychiatric
Press, Washington, D.C., 2009, pp. 483–506.
Watson DG, Lenox RH. Chronic lithium- induced downregulation
of MARCKS in immortalized hippocampal cells:
Potentiation by muscarinic receptor activation. J Neurochem,
1996, 67:767–777.
Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A
receptor inverse agonists as antipsychotics. J Pharmacol Exp
Ther, 2001, 299:268–276.
Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine
capsules as monotherapy in bipolar disorder:
Pooled results from two randomised, double- blind, placebocontrolled
trials. CNS Drugs, 2006, 20:219–231.
Williams RSB, Cheng L, Mudge AW, Harwood AJ. A common
mechanism of action for three mood- stabilizing drugs. Nature,
2002, 417:292–295.
Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition
in the treatment of mania: A double- blind, placebo- controlled
trial of tamoxifen. Arch Gen Psychiatry, 2008, 65: 255–263.
Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar
disorder during pregnancy and the postpartum period. Am
J Psychiatry, 2004, 161:608–620.
Zahodne LB, Fernandez HH. Course, prognosis, and management
of psychosis in Parkinson’s disease: Are current treatments
really effective? CNS Spectrums, 2008, 13:26–33.
Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein
kinase C inhibitor (tamoxifen) in the treatment of acute mania:
A pilot study. Bipolar Disord, 2007, 9:561–570.
CHAPTER 16
PHARMACOTHERAPY OF PSYCHOSIS AND MANIA
455